Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-05-17
2008-01-29
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S427000, C514S428000, C514S429000, C548S537000, C548S561000, C548S563000
Reexamination Certificate
active
07323490
ABSTRACT:
The invention provides pyrrole-containing compounds and methods of use thereof. Kits and pharmaceutical compositions comprising the pyrrole compounds of the invention are also provided. The compounds and compositions disclosed herein are preferably used in the treatment of neurodegenerative diseases, cardiovascular diseases, proliferative diseases, and visual disorders. In particular, methods and compositions for the treatment of stroke are disclosed herein.
REFERENCES:
patent: 2714082 (1955-07-01), Davies et al.
patent: 3803316 (1974-04-01), Bosshard et al.
patent: 3983140 (1976-09-01), Endo et al.
patent: 4137322 (1979-01-01), Endo et al.
patent: 4198425 (1980-04-01), Mitsui et al.
patent: 4255444 (1981-03-01), Oka et al.
patent: 4262013 (1981-04-01), Mistui et al.
patent: 4375475 (1983-03-01), Willard et al.
patent: 4572909 (1986-02-01), Campbell et al.
patent: 4596821 (1986-06-01), Cragoe, Jr. et al.
patent: 4604403 (1986-08-01), Cragoe, Jr. et al.
patent: 4605663 (1986-08-01), Cragoe, Jr. et al.
patent: 4605664 (1986-08-01), Cragoe, Jr. et al.
patent: 4647576 (1987-03-01), Hoefle et al.
patent: 4681893 (1987-07-01), Roth
patent: 4879303 (1989-11-01), Davison et al.
patent: 5003080 (1991-03-01), Butler et al.
patent: 5089514 (1992-02-01), Hulin
patent: 5097045 (1992-03-01), Butler et al.
patent: 5103024 (1992-04-01), Millar et al.
patent: 5124482 (1992-06-01), Butler et al.
patent: 5149837 (1992-09-01), Butler et al.
patent: 5155251 (1992-10-01), Butler et al.
patent: 5216174 (1993-06-01), Butler et al.
patent: 5245047 (1993-09-01), Butler et al.
patent: 5248793 (1993-09-01), Millar et al.
patent: 5260305 (1993-11-01), Dennick
patent: 5273995 (1993-12-01), Roth
patent: 5280126 (1994-01-01), Butler et al.
patent: 5298627 (1994-03-01), Butler et al.
patent: 5306726 (1994-04-01), Hulin
patent: 5342952 (1994-08-01), Butler et al.
patent: 5397792 (1995-03-01), Butler et al.
patent: 5656644 (1997-08-01), Adams et al.
patent: 5686104 (1997-11-01), Mills et al.
patent: 5969156 (1999-10-01), Briggs
patent: 5985884 (1999-11-01), Lohray et al.
patent: 6048883 (2000-04-01), Haigh et al.
patent: 6054453 (2000-04-01), Lohray et al.
patent: 6126971 (2000-10-01), Mills et al.
patent: 6130214 (2000-10-01), Lohray et al.
patent: 6166049 (2000-12-01), Smith
patent: 6274603 (2001-08-01), Poirier
patent: 6440966 (2002-08-01), Barrett et al.
patent: 6455574 (2002-09-01), Buch
patent: 6541636 (2003-04-01), Harada et al.
patent: 2003/0186221 (2003-10-01), Lockahart
patent: 2003/0199498 (2003-10-01), Lohray et al.
patent: 2003/0236254 (2003-12-01), Lohray et al.
patent: 2004/0009470 (2004-01-01), Lockhart
patent: 2004/0072893 (2004-04-01), Srinath et al.
patent: 2005/0014954 (2005-01-01), Ohrlein et al.
patent: 2005/0043357 (2005-02-01), Coleman et al.
patent: 0160891 (1985-11-01), None
patent: 0657426 (1995-06-01), None
patent: 1176140 (2004-12-01), None
patent: WO97/10217 (1997-03-01), None
patent: WO 03/027069 (2003-04-01), None
patent: WO03/086379 (2003-04-01), None
patent: WO 03/055479 (2003-07-01), None
patent: WO 03/057669 (2003-07-01), None
patent: WO 03/064411 (2003-08-01), None
patent: WO 03/082816 (2003-10-01), None
Ostrum, Kenneth G., Science IP The CAS Search Service, Apr. 4, 2005, 1-30, Columbus, OH.
Stanley, Kerry G., Science IP The CAS Search Service, Apr. 8, 2005, 1-33, Columbus, OH.
Bruce D. Roth, The Discovery and Development of Atorvastatin, a Potent Novel Hypolipidemic Agent, Progress in Medical Chemistry,2002, pp. 1-22, vol. 40.
Peter W.K. Woo, Atorvastatin, An HMG-COA Reductase Inhibitor and Effective Lipid-Regulating Agent Part III Synthesis of [2H3] [13C8], And [13C7,15N] Atorvastatin And Their Application in Metabolic And Pharmacokinetic Studies, Journal of Labelled Compounds and Radiopharmaceuticals, 1999, pp. 135-145, vol. 42.
Kebin Wu, Catalytic Properties of NAD(P) H : Quinone Oxidoreductase-2 (NQO2), a Dihydronicotinamide Riboside Dependent Oxidoreductase, 1997, pp. 221-228, vol. 347, No. 2 Article No. BB970344.
Paul R Graves, Discovery of Novel Targets of Quinoline Drugs in the Human Purine Binding Proteome, Molecular Pharmacology, pp. 1364-1372, vol. 62, No. 6.
Terry A Cook, The δ Subunit of Type 6 Phosphodiesterase Reduces Light-induced cGMP Hydrolysis in Rod Outer Segments, The Journal of Biological Chemistry, 2001, pp. 5248-5254, vol. 276, No. 7.
Vanessa Nancy, The δ Subunit of Retinal Rod cGMP Phosphodiesterase Regulates the Membrane Association of Ras and Rap GTPases, The Journal of Biological Chemistry, 2002, pp. 15076-15084, vol. 277, No. 17.
Houbin Zhang et al., Photoreceptor cGMP Phosphodiesterase δ Subunit (PDEδ) Functions as a Prenyl-binding Protein, The Journal of Biological Chemistry, 2004, pp. 407-413, vol. 279, No. 1.
Christine E. Foster, Structures of Mammalian Cytosolic Quinone Reductase, Free Radical Biology & Medicine, 2000, pp. 241-245, vol. 29, Nos. 3/4.
Krisztian J. Kapinya, Role of NAD(P)H:quinone oxidoreductase in the progression of neuronal cell death in vitro and the following cerebral ischaemia in vivo, Journal of Neurochemistry, 2003, pp. 1028-1039, vol. 84.
Ahlke Strassburg, Differential Gene Expression of NAD(P)H: Quinone Oxidoreductase and NRH: Quinone Oxidoreductase in Human Hepatocellular and Biliary Tissue, Molecular Pharmacology, 2002, pp. 32-325, vol. 61, No. 2.
Shiuan Chen, Structure-Function Studies of DT-Diaphorase (NQ01) And NRH: Quinone Oxidoreductase (NQ02), Free Radical Biology & Medicine, 2000, pp. 276-284, vol. 29, Nos. 3/4.
Richard J. Knox, Bioactivation of 5-(Aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by Human NAD(P)H Quinone Oxidoreductase 2: A Novel Co-substrate-mediated Antitumor Prodrug Therapy, 2000, pp. 4179-4186, vol. 60.
Delwin J. Long, NRH: quinone Oxidoreductase (NQO2), Chemical Biological Interactionns, 2000, pp. 99-112, vol. 129.
Christine E. Foster et al., Crystal Structure of Human Quinone Type 2, a Metalloflavoprotein, Biochemistry, 1999, pp. 9881-9886, vol. 38.
Serge N. Schiffmann et al., Impaired Motor Coordination and Purkinje cell excitability in mice lacking calretinin, Proc. Natl. Acad., pp. 5257-5262, vol. 96.
Masao Takemoto, Pleiotropic Effects of 3-Hydroxy-3 Methylglutaryl Coenzyme A Reductase Inhibitors, Arterioscler Thromb Vasc Biol, 2001, pp. 1712-1719.
James K. Liao, Beyond Lipid Lowering: The Role of Statins in Vascular Protection, International Journal of Cardiology, 2002, pp. 1-18, vol. 86.
James K. Liao, Isoprenoid As Mediators of the Biological Effects of Statins, The Journal of Clinical Investigation, 2002, pp. 285-288, vol. 110, No. 3.
Carl J. Vaughan, MD, Prevention of Stroke and Dementia With Statins: Effects Beyond Lipid Lowering, Am J. Cardiol, 2003, pp. 23B-29B.
Zhi Jun Zhang, A Selective Decrease in the Relative Density of Parvalbumin-immunoreactive Neurons in the hippocampus in Schizophrenia, Schizophrenia Research, 2002, pp. 1-10, vol. 55.
Jun-Ho Maeng, Ph.D., Trip Report: CU-Array Biopharma Symposium on Medicinal and Synthetic Organic Chemistry, 2001, pp. 1-10, vol. 6, No. 33.
Olivier Nosjean, Identification of the Melatonin-binding Site MT3as the Quinone Reductase 2, The Journal of Biological Chemistry, 2000, pp. 31311-31317, vol. 275, No. 4.
Olivier Nosjean, Comparative Pharmacological Studies of Melatonin Receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2, Biochemical Pharmacology, 2001, pp. 1369-1379, vol. 61.
Paula A Witt-Enderby, Melatonin Receptors and Their Regulation: Biochemical and Structural Mechanism, Life Sciences, 2003, pp. 2183-2198, vol. 72.
Shoji Harada, An Association between Idiopathic Parkinson's Disease and Polymorphisms of Phase II Detoxification Enzymes: Glutathione S- Transferase M1 and Quinone Oxidoreductase 1 and 2, Biochemical and Biophysical Research Communication, 2001,pp. 887-892, vol. 288.
Louis Renault et al., Co-expression, Copurification,crystallization and preliminary X-ray Analysis of a complex of ARL2-GTP and PDE δ, Crystallization papers, ISSN 0907-4449, 2001, pp. 1167-1170, Section D.
Pramod S. Pandey, An Efficient Synthesis of N3,4-dipheny-5-(4-fluorophenyl)-2-isopropyl-1H-3-pyrr
Biggs, III William H.
Ciceri Pietro
Fabian Miles A.
Lockhart David J.
Mehta Shamal Anil
Ambit Biosciences Corporation
Anderson Rebecca
Chu Yong
Jones Day
LandOfFree
Pyrrole compounds and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrole compounds and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrole compounds and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3965142